Video

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Author(s):

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Cathy Eng, MD, Vanderbilt University

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Aparna Parikh, MD
Related Content
Tanios S. Bekaii-Saab, MD
November 19th 2024

Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Sebastian Kaulitzki – stock.adobe.com
November 15th 2024

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Shaji Kumar, MD, research chair, Division of Hematology, consultant, Division of Hematology, professor, medicine, Mayo Clinic
November 6th 2024

Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More